Project Grant R21EY036552
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$191K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Fort Worth, TX 76107, USA
Similar Awards
This $185,000 Project Grant award from the National Eye Institute (NEI) under CFDA 93.867 (Vision Research) supports research to discover novel disease-modifying therapies for the prevention and treatment of glaucoma. The primary awardee, the University of North Texas Health Science Center at Fort Worth, will employ computational pharmacology approaches to identify small molecule inhibitors that can interfere with the GREM1-BMP protein-protein interaction, a key pathogenic mechanism contributing...
This federal Project Grant award of $387,428.00 from the National Eye Institute (CFDA 93.867 - Vision Research) supports research to investigate mechanisms that drive optic nerve sensitivity to elevated intraocular pressure, a major risk factor for optic nerve damage in glaucoma. The overarching goal is to determine how transient biomechanical strains on the optic nerve head prime astrocytes to develop greater glaucomatous dysfunction via the mechanosensitive channel Piezo1. The award will...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), supports research to investigate the role of myeloid cells in axon damage and degeneration associated with glaucoma. The research aims to determine whether NAD+-boosting interventions, which have shown promise in promoting axon protection, work through an anti-inflammatory mechanism by inhibiting myeloid cell recruitment. The award provides $423,767.00 over a 2-year period...
This federal Project Grant award of $618,088 from the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) will support research to investigate the role of mitochondrial DNA (mtDNA) and the DNA/RNA sensor ZBP1 in retinal neurodegeneration associated with glaucoma. The research team from the University of Texas Medical Branch at Galveston will use novel ZBP1 conditional knockout or overexpression mouse models, in vivo tracking of extracellular vesicles, and...
The National Eye Institute (NEI), through its Vision Research federal grant program (CFDA 93.867), awarded a $679,159 Project Grant to The Schepens Eye Research Institute, Inc. in Boston, Massachusetts. The grant, awarded on May 1, 2025, supports research aimed at understanding how aging and elevated intraocular pressure (IOP) contribute to the development of glaucoma and impact retinal ganglion cells (RGCs). The research project will investigate the transcriptomic changes in RGCs due to aging...
The National Eye Institute (NEI) awarded a $568,122 Project Grant under the Vision Research program (CFDA 93.867) to Baylor College of Medicine to conduct research on the role of vascular ligands and neurovascular dysfunction in glaucoma. The project aims to systematically identify endothelial cell-specific ligands that can modulate retinal ganglion cell function and survival in glaucoma, with the goal of developing novel neuroprotective therapies. The award period runs from July 1, 2025 to...
This Project Grant award of $2,260,440.00 from the National Eye Institute (CFDA 93.867 Vision Research) supports research to investigate the molecular, cellular, and transcriptional mechanisms that regulate reactive astrocyte behavior and its impact on retinal ganglion cell survival in a mouse model of glaucoma. The research aims to elucidate how compartmentalized cAMP signaling and associated factors like the cell cycle regulator p21CIP confer specificity to neurotoxic versus protective...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to enhance stem cell restoration of intraocular pressure (IOP) homeostasis in glaucoma through senolytic treatments. The $234,000 award to Oregon Health & Science University aims to use senolytics and senoreverters to restore TM cell IOP homeostatic function in glaucomatous tissue, with or without stem cell transplantation. This research has the...
This $460,625 Project Grant was awarded by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to Yale University. The grant will fund research to investigate the cellular and synaptic mechanisms underlying changes in retinal ganglion cell (RGC) activity following optic nerve injuries in mouse models of glaucoma. Specifically, the project aims to (1) determine the underlying mechanisms for altered RGC activity after increased intraocular pressure or...
This Project Grant award of $526,841 from the National Eye Institute (CFDA 93.867 - Vision Research) will support research at Vanderbilt University Medical Center (VUMC) to investigate the role of cGMP signaling in glaucomatous neurodegeneration. The goal is to probe the mechanisms of retinal ganglion cell (RGC) degeneration in glaucoma, a leading cause of irreversible blindness, in order to identify novel therapeutic targets to protect and potentially restore vision. The research will focus...